BioCryst Pharmaceuticals, Inc. (BCRX)
8.91
-0.19
(-2.09%)
USD |
NASDAQ |
May 29, 16:00
8.92
+0.01
(+0.11%)
After-Hours: 20:00
BioCryst Pharmaceuticals EPS Diluted (Quarterly) : -2.980 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Dyne Therapeutics, Inc. | -0.7323 |
| Taysha Gene Therapies, Inc. | -0.1157 |
| Agenus, Inc. | 1.023 |
| Amgen, Inc. | 3.344 |
| Anika Therapeutics, Inc. | -0.3737 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -721.81M |
| Revenue (Quarterly) | 156.41M |
| Total Expenses (Quarterly) | 878.22M |
| Enterprise Value | 2.883B |
| Gross Profit Margin (Quarterly) | 95.88% |
| Profit Margin (Quarterly) | -461.5% |
| Earnings Yield | -19.94% |
| Operating Earnings Yield | 15.74% |
| Normalized Earnings Yield | 3.358 |